BioNTech announced its Q2 2026 financial results, reporting €105.6 million in revenues, down from the previous year due to lower COVID-19 vaccine demand. The company appointed Guido Oelkers as the new CEO, effective by February 2027. BioNTech is advancing its oncology pipeline with 14 pivotal clinical trials and expects key data readouts later this year. It also received European approval for its new variant-adapted COVID-19 vaccine. The company revised its 2026 revenue guidance to €1.6–1.9 billion, reflecting market changes and ongoing pipeline investments.
Moderna's stock jumped 11% with no new company news, driven by strong retail sentiment and trading momentum rather than fundamentals. Meanwhile, BioNTech rose only 2%, lagging behind both Moderna and the broader biotech sector, highlighting a growing...
Moderna shares fell 7% to $135.22 following a sharp rise to a record $176.66, as traders took profits after a 392% gain year-to-date. The pullback is orderly with no new company updates; the recent rally was driven by positive phase 3 melanoma trial ...
